SGPL1 and neoplasm: Therefore, low SGPL1 levels can be expected in RMA cells because it is well known that the loss of SGPL1 enhances the emergence for malignancy and tumor cell resistance to chemotherapeutic drugs including cisplatin and daunorubicin, which were used in RMS treatment [38, 42].